| Persistence and evolution of SARS-CoV-2 in an immunocompromised host B Choi*, MC Choudhary*, J Regan, JA Sparks, RF Padera, X Qiu, ... New England Journal of Medicine 383 (23), 2291-2293, 2020 | 948 | 2020 |
| SARS-CoV-2 viral load is associated with increased disease severity and mortality J Fajnzylber, J Regan, K Coxen, H Corry, C Wong, A Rosenthal, D Worrall, ... Nature communications 11 (1), 1-9, 2020 | 703 | 2020 |
| Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 TN Starr, AJ Greaney, A Addetia, WW Hannon, MC Choudhary, ... Science 371 (6531), 850-854, 2021 | 641 | 2021 |
| SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms SA Clark, LE Clark, J Pan, A Coscia, LGA McKay, S Shankar, RI Johnson, ... Cell 184 (10), 2605-2617. e18, 2021 | 134 | 2021 |
| Duration of shedding of culturable virus in SARS-CoV-2 Omicron (BA. 1) infection J Boucau, C Marino, J Regan, R Uddin, MC Choudhary, JP Flynn, G Chen, ... New England Journal of Medicine 387 (3), 275-277, 2022 | 93* | 2022 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence characteristics of coronavirus disease 2019 (COVID-19) persistence and reinfection MC Choudhary, CR Crain, X Qiu, W Hanage, JZ Li Clinical Infectious Diseases 74 (2), 237-245, 2022 | 64* | 2022 |
| Virologic features of severe acute respiratory syndrome coronavirus 2 infection in children LM Yonker, J Boucau, J Regan, MC Choudhary, MD Burns, N Young, ... The Journal of infectious diseases 224 (11), 1821-1829, 2021 | 56 | 2021 |
| Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19) J Boucau, R Uddin, C Marino, J Regan, JP Flynn, MC Choudhary, G Chen, ... Clinical Infectious Diseases 76 (3), e526-e529, 2023 | 49* | 2023 |
| Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections MJ Siedner, J Boucau, RF Gilbert, R Uddin, J Luu, S Haneuse, T Vyas, ... JCI insight 7 (2), 2022 | 40 | 2022 |
| Iron-overload triggers ADAM-17 mediated inflammation in severe alcoholic hepatitis JS Maras, S Das, S Sharma, S Sukriti, J Kumar, AK Vyas, D Kumar, A Bhat, ... Scientific reports 8 (1), 10264, 2018 | 37 | 2018 |
| Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay J Regan, JP Flynn, MC Choudhary, R Uddin, J Lemieux, J Boucau, ... Open forum infectious diseases 9 (3), ofac022, 2022 | 31 | 2022 |
| Endothelial cell-derived TGF-β promotes epithelial-mesenchymal transition via CD133 in HBx-infected hepatoma cells P Rawal, H Siddiqui, M Hassan, MC Choudhary, DM Tripathi, V Nain, ... Frontiers in Oncology 9, 308, 2019 | 29 | 2019 |
| Identification of Indian sub-continent as hotspot for HCV genotype 3a origin by Bayesian evolutionary reconstruction MC Choudhary, V Natarajan, P Pandey, E Gupta, S Sharma, R Tripathi, ... Infection, Genetics and Evolution 28, 87-94, 2014 | 25 | 2014 |
| Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA. 1 attenuation DY Chen, CV Chin, D Kenney, AH Tavares, N Khan, HL Conway, GQ Liu, ... Nature, 1-3, 2023 | 23* | 2023 |
| Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 KW Chew, C Moser, ES Daar, DA Wohl, JZ Li, RW Coombs, J Ritz, ... Nature communications 13 (1), 4931, 2022 | 22* | 2022 |
| Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection B Saha, MC Choudhary, SK Sarin Aids 27 (14), 2191-2200, 2013 | 21 | 2013 |
| Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial MC Choudhary, KW Chew, R Deo, JP Flynn, J Regan, CR Crain, C Moser, ... Nature microbiology 7 (11), 1906-1917, 2022 | 20* | 2022 |
| Extracellular vesicles from hepatitis B patients serve as reservoir of hepatitis B virus DNA S Sukriti, MC Choudhary, JS Maras, S Sharma, S Thangariyal, A Singh, ... J Viral Hepat 26, 211-214, 2019 | 19 | 2019 |
| Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant MS Seaman, MJ Siedner, J Boucau, CL Lavine, F Ghantous, MY Liew, ... JCI insight 7 (19), 2022 | 18* | 2022 |
| Symptom and viral rebound in untreated SARS-CoV-2 infection R Deo, MC Choudhary, C Moser, J Ritz, ES Daar, DA Wohl, AL Greninger, ... Annals of Internal Medicine 176 (3), 348-354, 2023 | 15* | 2023 |
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical SchoolVerified email at bwh.harvard.edu
